Prognostic role of epidermal growth factor receptors’ expression in patients with i-ii stage of non-small cell lung cancer

Authors

  • A.P. Kolesnik Zaporizhzhia State Medical University, Ukraine,
  • A.I. Shevchenko Zaporizhzhia State Medical University, Ukraine,
  • V.A. Tumansky Zaporizhzhia State Medical University, Ukraine,
  • A.V. Evseev Zaporizhzhia State Medical University, Ukraine,
  • M.A. Shishkin Zaporizhzhia State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2310-1237.2013.2.17362

Keywords:

prognosis, epidermal growth factor receptor, survival

Abstract

Introduction:

According to the National Cancer Registry data, referring to the revised data in Ukraine, 17422 new cases of lung cancer and 13498 deaths from this malignant tumor were registered in Ukraine within 2010 [1]. Therefore, high level of incidence and low effectiveness of treatment require improvement of current diagnostic and treatment methods of lung cancer. Surgery is the main treatment method of lung cancer, which gives a chance to recover. However, even after surgical treatment disease progression develops in some patients, that denotes the biological diversity of patients with early stages of NSCLC. Molecular markers’ use for prognostic groups’ selection is one of the ways to solve the problem of individualized treatment. The most significant among great number of prognostic markers is the group of growth factor receptors [11]. In studied literature we found conflicting data on the prognostic role of epidermal growth factor receptors in patients with early-stage lung cancer.

Objective: The aim of our work was to determine the connection  of clinical and morphological patients’ characteristics with the expression of epidermal growth factor receptors of 1 and 2 types (EGFR, HER-2-neu) and also to analyze the influence of these factors on patients survival with early stages (I-II) of non-small cell lung cancer (NSCLC).

Materials and methods: 100 patients with early stages of NSCLC, who received treatment in Zaporozhye regional clinical oncological dispensary from June 2008 till June 2011, were recruited in this study. Among them there were 84 men (84%) and 16 women (16%). Mean age was 60,5 years (95% CI, 58,9-62,1). All patients received surgical treatment with subsequent microscopic examination of tumor tissue. Immunohistochemistry of the removed tumor was performed in all the patients to determine the expression of HER-2-neu, EGFR.

Results: Lack of expression of HER-2-neu was observed in 114 patients (64,4%). Expression (+) was detected in 30 patients, (+ +) and (+ + +) in 18 and 8 patients, respectively. HER2/Neu expression wasn’t detected in 7 patients. The absence of EGFR expression was observed in 13 patients. EGFR expression in 6-10% of cells (+) was observed in 15 patients, 10-50% (+ +) - in 31 patient, more than 50% (+ + +) - in 85 patients. In 33 patients the definition of EGFR expression was not carried out. There was no correlation between age, sex, tumor localization, histological type, tumor differentiation, pT and pN criteria with the level of  HER-2-neu expression. Also, there was no correlation between age, sex, tumor localization, histological type, tumor differentiation, pT and pN criteria with the level of EGFR expression.

One of the main criteria for prognostic value of the marker is its connection with survival. There was shown no difference between patients with lack or presence of HER-2-neu expression during connection analysis of cell staining intensity and survival in patients with І-ІІ stages of NSCLC and EGFR expression (log-rank = 0,18). However, there is a tendency toward an improvement in patients’ survival with a lack of Her-2-neu expression. Multivariate regression analysis was performed to evaluate prognostic value of different clinical and morphological criteria. Independent prognostic factors are histological tumor type (HR=-2,44, p=0,01) and the size of primary tumor (HR=2,97, p=0,003). Prognostic value of other factors, including the expression of growth factors receptors, is not clinically significant, although the borderline predictive value of EGFR expression is noted.

Conclusions: Therefore, considering the results of studies carried out in our clinic and the literature data, insufficient knowledge of epidermal growth factor receptors expression in patients with lung cancer is obvious. We have found no connection between clinical and morphological factors and overexpression of EGFR and HER-2-neu in patients with I-II stage of NSCLC.

References

Суховерша О.А. Рак легень ІІІа стадії: індивідуалізація лікування та прогнозу: автореф. дис. … д-ра мед. н.: 14.01.07 «Онкологія» / О.А. Суховерша. – Донецьк, 2008. – 35 с.

Бюлетень Національного канцер-реєстру №13 «Рак в Україні, 2010–2011: захворюваність, смертність, показники діяльності онкологічної служби» / Федоренко З.П., Гулак Л.О., Горох Ю.Л. и др. – 2012. – №13. – С. 72

Cox G. A biological staging model for operable non-small cell lung cancer / Cox G., Jones J.L., Andi A., et al. // Thorax. – 2001. – Vol. 56. – P. 561–566.

D’Amico T.A. Molecular Biologic Staging of Lung Cancer / D’Amico T.A. // Ann Thorac Surg. – 2008. – Vol. 85. – Р. 737–742.

D’Amico T.A. Molecular Biologic Substaging of Stage I Lung Cancer According to Gender and Histology / D’Amico T.A., Aloia T.A., Mary-Beth H. // Ann Thorac Surg. – 2000. – Vol. 69. – Р. 882–886.

D’Amico T.A. A biologic risk model for stage i lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers / D’Amico T. A., Massey M., Herndon J. E., et al. // J Thorac Cardiovasc Surg. – 1999. – Vol. 117. – Р. 736–743.

Hirsch F.R. Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis / Hirsch F.R., Varella-Garcia M., Bunn P.A., et al. // J Clin Oncol. – 2003. – Vol. 21, №20. – Р. 3798–3807.

Judith Moldvay. Predictive Survival Markers in Patients with Surgically Resected Non-Small Cell Lung Carcinoma / Judith Moldvay, Philippe Scheid, Pascal Wild et al. // Clin Cancer Res. – 2000. – Vol. 6. – Р. 1125–1134.

Meert A-P. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis / Meert A-P., Martin B., Delmotte P. et al. // Eur Respir J. – 2002. – Vol. 20. – Р. 975–981.

Onn A. Tumor Cavitation in Stage I Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome1 / Onn A., Choe D.H., Herbst R.S.// Tumor Cavitation in Lung Cancer Radiology – October 2005

Taillade L. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer / Taillade L., Penault-Llorca F., Boulet T. et al. // Annals of Oncology. – 2007. – Vol. 18. – Р. 1043–1050.

Downloads

How to Cite

1.
Kolesnik A, Shevchenko A, Tumansky V, Evseev A, Shishkin M. Prognostic role of epidermal growth factor receptors’ expression in patients with i-ii stage of non-small cell lung cancer. Pathologia [Internet]. 2013Sep.30 [cited 2024Nov.2];(2). Available from: http://pat.zsmu.edu.ua/article/view/17362

Issue

No. 2 (2013)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Лицензия Creative Commons
    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).